Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Small Cell Lung Carcinoma 62Leukemia, Myeloid, Acute 14Carcinoma, Non-Small-Cell Lung 14Lung Neoplasms 10Lymphoma, Non-Hodgkin 9Lymphoma, Large B-Cell, Diffuse 9Recurrence 8Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 6Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 3Leukemia 3Hodgkin Disease 3Extensive Stage Small Cell Lung Cancer 3Carcinoma, Small Cell 3Small Cell Lung Cancer Extensive Stage 2SCLC 2Osteosarcoma 2Neoplasm Metastasis 2Lymphoma, B-Cell 2Lymphatic Diseases 2Immunoproliferative Disorders 2Hematologic Diseases 2Glioblastoma 2Ependymoma 2Advanced Solid Tumors 2Widespread Small Cell Lung Cancer 1Unresectable Locally Advanced or Metastatic Solid Tumors 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

dacetuzumab 6Rituximab 6blinatumomab 4ibrutinib 3Ifosfamide 3Bortezomib 3ponatinib 2cobomarsen 2Vorinostat 2Lenalidomide 2Etoposide 2Dexamethasone 2Carboplatin 2tetulomab tetraxetan lu-177 1pegaspargase 1ficlatuzumab 1enzalutamide 1durvalumab 1cirmtuzumab 1asparaginase erwinia chrysanthemi recombinant 1acalabrutinib 1Vincristine 1Prednisone 1Methotrexate 1Lutetium 1KW-2478 1Imatinib Mesylate 1Hsp90 inhibitor KU757 1Gemcitabine 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Immunoproliferative Disorders × Etoposide × Clear all
NCT02592876 2019-05-17

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Seagen Inc.

Phase 2 Terminated
81 enrolled 15 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00529503 2015-02-25

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Seagen Inc.

Phase 2 Terminated
151 enrolled
Lymphoid

Hematologic Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡